Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity

Abstract Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosine. CD39 is expressed by different immune...

Full description

Bibliographic Details
Main Authors: Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski, Alfred Zippelius
Format: Article
Language:English
Published: BMJ Publishing Group 2019-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
CD39
CD73
Ectonucleotidase
Antisense oligonucleotide (ASO)
Immunotherapy
ATP
Online Access:http://link.springer.com/article/10.1186/s40425-019-0545-9

Internet

http://link.springer.com/article/10.1186/s40425-019-0545-9

Similar Items